In vitro metabolism of an orally active O-methyl amidoxime prodrug for the treatment of CNS trypanosomiasis - PubMed (original) (raw)
In vitro metabolism of an orally active O-methyl amidoxime prodrug for the treatment of CNS trypanosomiasis
J H Ansede et al. Xenobiotica. 2005 Mar.
Abstract
A new aza-analogue of furamidine, 6-[5-(4-amidinophenyl)-furan-2-yl]nicotinamidine (DB820), has potent in vitro antitrypanosomal activity; however, it suffers from poor oral activity because of its positively charged amidine groups. The dimethoxyamidine prodrug of DB820, N-methoxy-6-{5-[4-(N-methoxyamidino)phenyl]-furan-2-yl}-nicotinamidine (DB844), has potent oral activity in mouse models of both early-stage and CNS African trypanosomiasis. Metabolism of DB844 in human liver microsomes (HLM) was investigated using liquid chromatography-mass spectrometry (LC-MS/MS). The metabolism of DB844 in HLM was NADPH-dependent and resulted in the production of eight metabolites over a 90?min incubation. O-Demethylation and N-dehydroxylation reactions resulted in the metabolic conversion of DB844 to its active DB820 metabolite. Chromatographic conditions used for LC-MS analysis allowed for the separation and identification of all metabolites including positional isomers. Demethylation of either the phenyl or pyridine side of DB844 (DB844 m/z 366.2) resulted in the production of two metabolites (M1A, M1B), each with a molecular ion of m/z of 352.3 and MS(2) fragments of 288.1, 305.2, 321.2 and 335.2. However, the intensities of the MS(2) fragments were different among the two isomeric metabolites, and comparison to an authentic standard allowed for the structural determination of each metabolite. The isomeric metabolites M2A and M2B, resulting from amidoxime reductions of M1A and M1B, were also chromatographically separated and had distinguishable MS(2) profiles that allowed for their structural assignments when compared to an authentic standard. The di-amidoxime product resulting from O-demethylation of either side of DB844 was also identified as an abundant metabolite during microsomal incubations. The active antitrypanosomal metabolite, DB820, was the last metabolite to be formed and thus provides evidence that DB844 may effectively be metabolized to its active metabolite in vivo.
Similar articles
- CYP1A1 and CYP1B1-mediated biotransformation of the antitrypanosomal methamidoxime prodrug DB844 forms novel metabolites through intramolecular rearrangement.
Ju W, Yang S, Ansede JH, Stephens CE, Bridges AS, Voyksner RD, Ismail MA, Boykin DW, Tidwell RR, Hall JE, Wang MZ. Ju W, et al. J Pharm Sci. 2014 Jan;103(1):337-49. doi: 10.1002/jps.23765. Epub 2013 Nov 1. J Pharm Sci. 2014. PMID: 24186380 Free PMC article. - Pharmacology of DB844, an orally active aza analogue of pafuramidine, in a monkey model of second stage human African trypanosomiasis.
Thuita JK, Wang MZ, Kagira JM, Denton CL, Paine MF, Mdachi RE, Murilla GA, Ching S, Boykin DW, Tidwell RR, Hall JE, Brun R. Thuita JK, et al. PLoS Negl Trop Dis. 2012;6(7):e1734. doi: 10.1371/journal.pntd.0001734. Epub 2012 Jul 24. PLoS Negl Trop Dis. 2012. PMID: 22848769 Free PMC article. - Accumulation and intracellular distribution of antitrypanosomal diamidine compounds DB75 and DB820 in African trypanosomes.
Mathis AM, Holman JL, Sturk LM, Ismail MA, Boykin DW, Tidwell RR, Hall JE. Mathis AM, et al. Antimicrob Agents Chemother. 2006 Jun;50(6):2185-91. doi: 10.1128/AAC.00192-06. Antimicrob Agents Chemother. 2006. PMID: 16723581 Free PMC article. - Diamidines for human African trypanosomiasis.
Paine MF, Wang MZ, Generaux CN, Boykin DW, Wilson WD, De Koning HP, Olson CA, Pohlig G, Burri C, Brun R, Murilla GA, Thuita JK, Barrett MP, Tidwell RR. Paine MF, et al. Curr Opin Investig Drugs. 2010 Aug;11(8):876-83. Curr Opin Investig Drugs. 2010. PMID: 20721830 Review. - DB-289 Immtech International.
Yeates C. Yeates C. IDrugs. 2003 Nov;6(11):1086-93. IDrugs. 2003. PMID: 14600842 Review.
Cited by
- New Drugs for Human African Trypanosomiasis: A Twenty First Century Success Story.
Dickie EA, Giordani F, Gould MK, Mäser P, Burri C, Mottram JC, Rao SPS, Barrett MP. Dickie EA, et al. Trop Med Infect Dis. 2020 Feb 19;5(1):29. doi: 10.3390/tropicalmed5010029. Trop Med Infect Dis. 2020. PMID: 32092897 Free PMC article. Review. - Novel lead compounds in pre-clinical development against African sleeping sickness.
Berninger M, Schmidt I, Ponte-Sucre A, Holzgrabe U. Berninger M, et al. Medchemcomm. 2017 Jul 31;8(10):1872-1890. doi: 10.1039/c7md00280g. eCollection 2017 Oct 1. Medchemcomm. 2017. PMID: 30108710 Free PMC article. Review. - Chemotherapy of second stage human African trypanosomiasis: comparison between the parenteral diamidine DB829 and its oral prodrug DB868 in vervet monkeys.
Thuita JK, Wolf KK, Murilla GA, Bridges AS, Boykin DW, Mutuku JN, Liu Q, Jones SK, Gem CO, Ching S, Tidwell RR, Wang MZ, Paine MF, Brun R. Thuita JK, et al. PLoS Negl Trop Dis. 2015 Feb 5;9(2):e0003409. doi: 10.1371/journal.pntd.0003409. eCollection 2015 Feb. PLoS Negl Trop Dis. 2015. PMID: 25654243 Free PMC article. - The mammalian molybdenum enzymes of mARC.
Ott G, Havemeyer A, Clement B. Ott G, et al. J Biol Inorg Chem. 2015 Mar;20(2):265-75. doi: 10.1007/s00775-014-1216-4. Epub 2014 Nov 26. J Biol Inorg Chem. 2015. PMID: 25425164 Review. - CYP1A1 and CYP1B1-mediated biotransformation of the antitrypanosomal methamidoxime prodrug DB844 forms novel metabolites through intramolecular rearrangement.
Ju W, Yang S, Ansede JH, Stephens CE, Bridges AS, Voyksner RD, Ismail MA, Boykin DW, Tidwell RR, Hall JE, Wang MZ. Ju W, et al. J Pharm Sci. 2014 Jan;103(1):337-49. doi: 10.1002/jps.23765. Epub 2013 Nov 1. J Pharm Sci. 2014. PMID: 24186380 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources